- Price
- $10.30
- Day
- +3.41%
- Mkt Cap
- $532.48M
- 52W Range
- $5.46 – $16.19
- Volume
- 967.6K
- Beta
- 0.90
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m.
Read full article
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
Read full article
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Regenxbio, Inc. provided investors with false and/or misleading information regarding the efficacy and safety of its trial study for RGX-111, a one-time gene therapy for the treatment of Hurler Syndrome, including positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study.
Read full article
REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Read full article
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Speciali
Read full article
One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids Prevention of vision-threatening events without any additional treatment and > 2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids Topline data from wet AMD pivotal studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026 ROCKVILLE, Md.,, July 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD using subretinal delivery and diabetic retinopathy (DR) using suprachoroidal delivery.
Read full article
ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions.
Read full article
ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering.
Read full article